	US 12,325,871 B2
	Lysosomal enzymes modified by cell based glycoengineering
Claus Kristensen, Bronshoj (DK); Weihua Tian, Hvidovre (DK); Henrik Clausen, Copenhagen (DK); Zhang Yang, Gentofte (DK); and Sergey Vakhrushev, Nyborg (DK)
Assigned to University of Copenhagen, Copenhagen (DK); and GLYCODISPLAY APS, Copenhagen (DK)
Filed by University of Copenhagen, Copenhagen (DK); and GLYCODISPLAY APS
Filed on May 19, 2023, as Appl. No. 18/199,575.
Application 18/199,575 is a continuation of application No. 17/272,178, granted, now 11,708,569, previously published as PCT/US2019/048854, filed on Aug. 29, 2019.
Claims priority of provisional application 62/724,543, filed on Aug. 29, 2018.
Prior Publication US 2023/0416715 A1, Dec. 28, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/40 (2006.01); C12P 21/00 (2006.01)

CPC C12N 9/2465 (2013.01) [C12P 21/005 (2013.01); C12Y 302/01022 (2013.01); C12Y 302/01045 (2013.01)]

13 Claims

1. A modified recombinant lysosomal enzyme with increased circulation time in plasma as compared to an unmodified version of the same, wherein said enzyme comprises low mannose-6-phosphate (Man6P) and high sialic acid (SA) capping of alpha2,3 type (alpha2,3SA), wherein said enzyme comprises more than 4 mol alpha2,3SA per mol of enzyme.